Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Key Inclusion Criteria:

• HIV-1 RNA ≥ 500 copies/mL at screening.

• Antiretroviral (ARV) treatment-naive, except the use of oral pre-exposureprophylaxis (PrEP) or postexposure prophylaxis (PEP) with emtricitabine/tenofovirdisoproxil fumarate (FTC/TDF) or F/TAF, up to 1 month prior to screening.

Key Exclusion Criteria:

• Prior use of any long acting parenteral antiretrovirals (ARVs) such as monoclonalantibodies, broadly neutralizing antibodies targeting HIV-1, LEN, injectablecabotegravir (including oral cabotegravir lead-in), and/or injectable rilpivirine.

• Documented resistance to the integrase strand-transfer inhibitor class,specifically, resistance-associated mutations E92G/Q, G118R, F121Y, Y143C/H/R,S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene.

• Any of the following laboratory values at screening:

1. CD4 cell count < 200 cells/mm3 at screening.

2. Estimated glomerular filtrations arate < 60 mL/min according to theModification of Diet in Renal Disease formula.

3. Hepatic transaminases (aspartate aminotransferase and alanine aminotransferase) > 1.5 × upper limit of normal (ULN).

4. Direct bilirubin > 1.5 × ULN.

5. Platelets count < 50,000 cells/mm3.

6. Hemoglobin < 8.0 g/dL.

• Active or occult hepatitis B virus infection.

• Active hepatitis C virus infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.